Andra AP fonden Raises Position in Medtronic PLC $MDT

Andra AP fonden lifted its stake in Medtronic PLC (NYSE:MDT) by 94.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 62,629 shares of the medical technology company’s stock after purchasing an additional 30,400 shares during the quarter. Andra AP fonden’s holdings in Medtronic were worth $5,459,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MDT. Brighton Jones LLC boosted its stake in shares of Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the period. Stratos Wealth Advisors LLC lifted its stake in Medtronic by 4.5% in the first quarter. Stratos Wealth Advisors LLC now owns 6,855 shares of the medical technology company’s stock worth $616,000 after purchasing an additional 293 shares during the last quarter. Alps Advisors Inc. lifted its stake in Medtronic by 1.1% in the first quarter. Alps Advisors Inc. now owns 27,427 shares of the medical technology company’s stock worth $2,465,000 after purchasing an additional 290 shares during the last quarter. Cerity Partners LLC boosted its position in shares of Medtronic by 122.1% during the first quarter. Cerity Partners LLC now owns 573,034 shares of the medical technology company’s stock valued at $51,495,000 after buying an additional 315,066 shares during the period. Finally, MJP Associates Inc. ADV grew its stake in shares of Medtronic by 36.5% during the first quarter. MJP Associates Inc. ADV now owns 9,214 shares of the medical technology company’s stock valued at $828,000 after buying an additional 2,463 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the completion of the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.26% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research analyst reports. Sanford C. Bernstein reissued an “outperform” rating and set a $98.00 price target on shares of Medtronic in a research note on Friday, October 31st. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Medtronic in a research note on Thursday, August 14th. BTIG Research reiterated a “neutral” rating on shares of Medtronic in a research report on Friday, July 11th. Finally, Argus upped their price target on shares of Medtronic from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $102.82.

Medtronic Stock Up 2.4%

Shares of Medtronic stock opened at $92.22 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The stock has a market cap of $118.29 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 2.42 and a beta of 0.77. The firm’s 50-day moving average is $94.20 and its two-hundred day moving average is $89.96. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, August 19th. The medical technology company reported $1.26 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.03. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.58 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter in the prior year, the company earned $1.23 EPS. The company’s revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 17th. Shareholders of record on Friday, September 26th were given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.